Short-chain acyl-CoA dehydrogenase deficiency (SCAD) is a rare inherited metabolic disorder caused by a deficiency in a specific enzyme required for fatty acid oxidation. This enzyme, SCAD, plays a key role in the oxidation of fatty acids with carbon chains of 4 to 16 carbon atoms, providing the cell with energy. SCAD results in the accumulation of acyl-CoA derivatives, which can cause serious clinical manifestations, especially in early childhood. Symptoms can range from hypoglycemia and vomiting to more serious manifestations such as cardiomyopathy and coma, making prompt diagnosis and treatment critical for patients with this disorder.
History of the disease and interesting historical facts
Short-chain acyl-CoA dehydrogenase deficiency was first described in the medical literature in the early 1990s, when advances in molecular biology and genetics allowed scientists to identify mutations in the ACAD8 gene encoding the enzyme. One of the first studies on the disorder was conducted in 1996, where the clinical spectrum of manifestations and molecular mechanisms leading to its development were studied. Interestingly, in some cases, the diagnosis of SCAD was made only after the death of the patients, when genetic and biochemical studies were carried out. This highlights the importance of earlier diagnosis and understanding of the mechanisms of the disorder. Since then, many studies have been conducted identifying mutations, pathogenesis and clinical characteristics of the disease, which has significantly increased awareness of the disorder.
Epidemiology
Short-chain acyl-CoA dehydrogenase deficiency is a rare disorder with an incidence of approximately 1 in 10,000 to 20,000 live births. The incidence may vary among populations: for example, the disease is less common in European populations than in African and Arab populations. According to various studies, CCHD accounts for only a small proportion of all inherited metabolic disorders, but requires careful monitoring and early diagnosis due to the severity of clinical manifestations and the possibility of a fatal outcome. National neonatal screening programs help to identify the disease as early as possible, which in turn increases the chances of effective treatment and a positive outcome.
Genetic predisposition to this disease
Short-chain acyl-CoA dehydrogenase deficiency is an autosomal recessive disorder, meaning that mutations in both alleles of the ACAD8 gene are required for the disorder to manifest. To date, more than 20 different mutations in this gene have been identified, which can cause either a complete absence of enzyme activity or a partial reduction in it. The most common mutations include point substitutions and deletions, which produce different phenotypes of the disease. Some studies have also linked the presence of specific mutations to a more severe course of the disease. The ACAD8 gene is located on chromosome 9 and is responsible for encoding short-chain acyl-CoA dehydrogenase, which emphasizes the importance of molecular genetic testing for diagnosis and understanding the pathogenesis of this disease.
Risk factors for the development of this disease
The main risk factor for developing short-chain acyl-CoA dehydrogenase deficiency is genetic predisposition, as the disease is inherited from carrier parents. The following risk factors are also noted:
- Consanguineous marriages, which increase the likelihood of inheriting recessive genes.
- Previous cases of the disease in the family, which dictates the need for monitoring and genetic counseling.
- Environmental factors and living conditions of the mother during pregnancy that may predispose to various metabolic disorders.
- Some specific metabolic diseases that may complicate the course of DCC.
Diagnosis of this disease
To diagnose short-chain acyl-CoA dehydrogenase deficiency, a comprehensive approach is used, including both clinical studies and laboratory and instrumental methods. The main symptoms to pay attention to are:
- Hypogrammia is a pathologically low level of sugar in the blood.
- Hypotension is a decrease in muscle tone.
- Symptoms associated with muscle weakness and fatigue.
- Clinical signs of cardiomyopathy such as shortness of breath and edema.
- Episodes of vomiting and refusal to eat.
Laboratory tests include:
- Biochemical tests to determine acyl-CoA levels in the blood.
- Genetic testing for mutations in the ACAD8 gene.
Radiological examinations may be useful to exclude other pathologies, such as heart disease. It is important to conduct a differential diagnosis with other forms of metabolic disorders, including other types of acyl-CoA dehydrogenases, to exclude their presence and determine the correct course of treatment.
Treatment
Treatment of short-chain acyl-CoA dehydrogenase deficiency is multifaceted and requires an individual approach depending on the clinical picture:
- General treatment includes dietary therapy with increased carbohydrate intake and reduced fat levels in the diet.
- Pharmacological treatment may include the use of dexamethasone and other corticosteroids to correct metabolic status.
- Surgical intervention may be necessary in cases where there are severe cardiovascular disorders that require correction.
- Other treatments, such as supportive care and prompt emergency interventions in case of crises, also play an important role.
List of medications used to treat this disease
Drugs recommended for the treatment of DCC include:
- Dexamethasone – used to correct metabolic processes.
- Glucose – used in case of hypoglycemic crises.
- Substrate fat supplements – in limited quantities to improve metabolism.
Disease monitoring
Monitoring of patients with short-chain acyl-CoA dehydrogenase deficiency requires regular monitoring of metabolic status:
- Monitor blood sugar levels to prevent hypoglycemic episodes.
- Regular examinations by a cardiologist to identify possible cardiovascular complications.
- Laboratory studies on the dynamics of acyl-CoA levels in the blood.
- The prognosis with adequate monitoring and therapy is usually good, but complications are possible, especially those related to the heart and metabolism.
Age-related features of the disease
Short-chain acyl-CoA dehydrogenase deficiency can manifest itself in various age groups, but the most severe symptoms are often observed in newborns and infants. In adults, symptoms may manifest themselves to a much lesser extent, which sometimes complicates diagnosis. In elderly patients, DCCA may be accompanied by existing pathologies, which requires a comprehensive approach to treatment and monitoring.
Questions and Answers
- What is short-chain acyl-CoA dehydrogenase deficiency? It is a rare inherited disorder caused by a lack of a specific enzyme needed to oxidize fatty acids.
- What are the main symptoms of the disease? The main symptoms include hypoglycemia, muscle weakness, vomiting and signs of cardiomyopathy.
- How is DCC diagnosed? Diagnosis includes biochemical tests, genetic testing and clinical examination.
- What risk factors predispose to the disease? The main risk factors are genetic predisposition and the presence of cases of the disease in the family.
- What is the most effective treatment for DCC? Treatment includes diet therapy, pharmacological drugs and, if necessary, surgery.
